Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melarsomine dihydrochloride is an organic arsenical compound used in veterinary medicine for the treatment of heartworm disease caused by *Dirofilaria immitis* in dogs. It is the only FDA-approved adulticide for this indication. The drug acts by interfering with the metabolism of the parasite, specifically targeting adult and late-stage immature heartworms, likely through the inhibition of sulfhydryl-containing enzymes essential for glycolysis and energy production. It is administered via deep intramuscular injection into the epaxial (lumbar) muscles. Due to the potential for arsenic toxicity and the risk of pulmonary thromboembolism as the worms die, treatment requires strict exercise restriction and careful clinical monitoring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melarsomine dihydrochloride.